Selecting Frontline Therapy for High-Risk EGFR-Mutated NSCLC

August 20, 2026

This segment works through what actually drives frontline treatment selection in EGFR-mutated advanced non-small cell lung cancer. Symptom burden serves as a surrogate for tumor burden, alongside brain and liver metastases and circulating tumor DNA detectable at diagnosis, read as another marker of high burden. Comorbidities and age carry as much weight as biology: no fixed age cutoff applies, but osimertinib monotherapy may remain the choice for an older patient with poor prognostic features, and younger working patients may find regular infusions impractical, making shared decision-making central. The discussion then turns to the TOP trial, which enrolled patients with EGFR and TP53 co-mutations and randomly assigned them to osimertinib with or without platinum-pemetrexed, favoring the combination on progression-free survival. Its prospective, biomarker-selected design stands out against otherwise retrospective data, though translation beyond a largely Chinese population remains unsettled.